Related references
Note: Only part of the references are listed.Promoting innovation while controlling cost: The UK's approach to health technology assessment
Michael Anderson et al.
HEALTH POLICY (2022)
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Amanda J. Kerr et al.
CANCER TREATMENT REVIEWS (2022)
Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
Debra Patt et al.
CLINICAL BREAST CANCER (2022)
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Benjamin James Hall et al.
BREAST JOURNAL (2022)
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
Mark P. Lythgoe et al.
JAMA NETWORK OPEN (2022)
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
Salma El Badri et al.
BREAST (2021)
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Avi Cherla et al.
JAMA INTERNAL MEDICINE (2021)
Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018
Mengyuan Fu et al.
JAMA INTERNAL MEDICINE (2021)
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
Michela Piezzo et al.
PHARMACEUTICS (2021)
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
Sushmita Rath et al.
PLOS ONE (2021)
Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
Katalin Boer et al.
ONCOTARGETS AND THERAPY (2021)
Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices
Junji Lin et al.
FUTURE ONCOLOGY (2021)
Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset
Chloe J. Bright et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England
Melissa Ruth Gannon et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis
Chandra P. Leo et al.
CANCERS (2020)
Real-world evidence use in assessments of cancer drugs by NICE
Ash Bullement et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)
Treatment variation in early breast cancer in the UK
David Dodwell et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Peter A. Fasching et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States
Emily M. Miller et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis
Helen J. Curtis et al.
BRITISH JOURNAL OF CANCER (2018)
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
Kimberly Blackwell et al.
CLINICAL BREAST CANCER (2018)
NICE, the NHS, and Cancer Drugs
Andrew Dillon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cohort profile: prescriptions dispensed in the community linked to the national cancer registry in England
Katherine E. Henson et al.
BMJ OPEN (2018)
Assessing the impact of NICE guidance on the prescribing of hormonal treatments of breast cancer in England
Raymond W. Fitzpatrick et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2015)
Conducting interrupted time-series analysis for single- and multiple-group comparisons
Ariel Linden
STATA JOURNAL (2015)
Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score
J. N. Armitage et al.
BRITISH JOURNAL OF SURGERY (2010)
The role of NICE technology appraisal in NHS rationing
Simon Walker et al.
BRITISH MEDICAL BULLETIN (2007)
What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews
TA Sheldon et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)